

HBV DNA integration: Consequences for Viral Gene Expression and Cellular Gene Dysregulation


Dr. Thomas Tu, Ph.D.

Viral Hepatitis Molecular Pathogenesis Lab, Storr Liver Centre

t.tu@sydney.edu.au

Westmead Institute for Medical Research, Sydney, Australia

HBV replication




Tu et al. 2018, J Virol
Tu et al. 2021, JHEP Rep

HBV DNA integration

- Random site in host genome at low rates (1 per 10^4 cells)
- Integrated HBV DNA is linked with HCC (>60% tumours)
 - Can drive expression of downstream genes → *cis*-activation
 - May code for mutated proteins → *trans*-activation

Tu et al. 2015, Liver Int.; Tu et al. 2017, Biol. Chem.

Integrated dsDNA (replication-deficient)




Tu et al. 2018, Viruses

Inverse nested PCR to detect HBV integration



Extract & sequence bands to confirm virus-cell junction

Quantitative



Unique junctions = clonal fingerprint

Repeated integration sites = clonal expansion

Yang and Surin 1999, JVI

Mason et al. 2010, JVI

Tu et al. 2015, JVI

Tu and Urban 2018, JVI


Tu et al. 2018, JVI

Tu and Urban 2018, JVI

Serially dilute DNA prior to nested PCR

Integration frequency determined by end-point titration

Cells with HBV integrations clonally expand




Hypotheses




Selection advantage of hepatocytes is driven by HBV DNA integrations via:

- 1) *cis*-mediated (site-dependent) mechanisms
- 2) *trans*-mediated (site-independent) mechanisms
- 3) Associative (not causative) mechanisms

Null hypothesis: integrations before expansion



Integrations occur <3dpi and do not increase over time




Expansion not likely due to cis-mediated mechanisms

No enrichment in:

- Expressed vs. non-expressed genes
- Transcriptional start sites
- Functional pathways

Where integrations occur does not play a role!



**Magdalena
Budzinska**
PhD

Budzinska, ... Tu, 2018,
Emer. Micro. & Infect.
Budzinska, ... Tu, 2018,
Genes

Expansion not likely due to trans-mediated mechanisms

From 24 tumour and 63 non-tumour samples from HBV patients:

- Detected 43 integrations in total
- 6 and 7 highly clonal integrations in non-tumour and tumour
- Specific Sanger sequencing of integrated HBV DNA show no mutational differences between tumour and non-tumour



**Monica
Pinkerton**
Honours student

What integrates does not play a role!

Tu et al., in preparation

HBV DNA integration frequency and HCC risk

- 33 anti-HBc⁺ and HBe⁻ patients (~20% on NA)
- Analysed non-tumour liver tissue

Group 1A = HBsAg⁺ w/o HCC (n=3)

Group 2A = HBsAg⁺ w/ HCC (n=15)

Group 1B = HBsAg⁻ w/o HCC (n=6)

Group 2B = HBsAg⁻ w/ HCC (n=9)

N.B. Liver from Groups 1A & 2B collected during resection of metastatic colorectal cancer.



Hung-Wen Tsai

Ih-Jen Su

Chiao-Fang Teng


Tu et al., in preparation

Integration frequency **not** linked to HCC

Integration frequency in non-tumour liver not associated with:

- HBsAg-loss
- HCC occurrence

No clear associative link



Tu et al., in preparation

Are HBV integrations associated with phenotypical cellular changes?



Ulrike Protzer




Jochen Wettengel

Sally Coulter
Research Officer




Vikki Ho
Research Assistant

Q: Are cells with HBV integrations functionally different?



Coulter et al., in preparation


Cells with integrations grow slower, show more DNA damage, and less DNA repair



Slower growth by live-imaging

Higher γ H2AX (DNA damage)

Poorer induction P-ATM (DNA repair)



Q: Does phenotype occur **before** or **after** integration?

Coulter et al., in preparation



Conclusions

Extensive clonal expansion occurs in cells with integration

HBV integration site, form, or frequency in non-tumour tissue does not appear to be associated with HCC

Still open question as to why HCC appear to contain more HBV DNA integrations than general hepatocyte population

Are integrations more likely to occur in cells with oncogenic potential?

Acknowledgements



Jacob George
Mark Douglas

Vikki Ho

Sally Coulter

Monica Pinkerton


Yuanyuan Liu

Rifqiyah Nur Umami


Vaishnavi Veeraraghavan

Henrik Zhang

Iram Aftab



Viral Hepatitis Group



Stephan Urban

Benno Zehnder

Bingqian Qu

Florian Lempp

Yi Ni



UniversitätsKlinikum
Heidelberg

Katrin Schöneweis

Lisa Walter

Funding:



Australian Government
National Health and
Medical Research Council



Australian Centre for
HIV and Hepatitis Virology Research



German Center
for Infection Research



Hung-Wen Tsai

Ih-Jen Su

Chiao-Fang Teng



Ulrike Protzer

Jochen Wettengel